Favipiravir（T-705）在狂犬病暴露后预防处置中的有效性  

Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis

作　　者：Yamada K Noguchi K Komeno T 吕新军 唐浏英 

机构地区：[1]Research Promotion Institute Department of Microbiology, Faculty of Medicine, Oita University, Yufu City Department of Food Science and Technology, Minami Kyushu University, Miyazaki City Research Laboratories, Toyama Chemical, Toyama City, Japan

出　　处：《中华实验和临床病毒学杂志》2017年第4期324-324,共1页Chinese Journal of Experimental and Clinical Virology

摘　　要：狂犬病是由狂犬病病毒引起的致死性脑炎，目前还没有针对狂犬病病毒的抗病毒药物。Favipiravir（T-705）是一种病毒RNA聚合酶抑制剂，对多种RNA病毒有抗病毒活性。Favipiravir（T-705）在体外和体内的抗狂犬病病毒作用在本研究中被首次证实。Rabies is a fatal encephalitis caused by rabies virus (RABV), and no antiviral drugs for RABV are currently available. We report for the first time the efficacy of favipiravir (T-705) against RABV in vitro and in vivo. T-705 produced a significant, 3-4 log₁₀ reduction in the multiplication of street and fixed RABV strains in mouse neuroblastoma Neuro-2a cells, with half-maximal inhibitory concentrations of 32.4 μM and 44.3 μM, respectively. T-705 significantly improved morbidity and mortality among RABV-infected mice when orally administered at a dose of 300 mg/kg/day for 7 days, beginning 1 hour after inoculation. T-705 significantly reduced the rate of virus positivity in the brain. Furthermore, the effectiveness of T-705 was comparable to that of equine rabies virus immunoglobulin for postexposure prophylaxis. Collectively, our results suggest that T-705 is active against RABV and may serve as a potential alternative to rabies immunoglobulin in rabies postexposure prophylaxis.

关 键 词：狂犬病病毒 暴露后预防 有效性 RNA聚合酶抑制剂 抗病毒药物 抗病毒活性 RNA病毒 病毒作用 

分 类 号：R512.99[医药卫生—内科学]